HOOK News and Press, HOOKIPA Pharma Inc. From 03/22/21

Do You Have These Top Biotech Stocks On Your Watchlist? It goes without saying that the biotech sector remains a crucial aspect of the broader healthcare industry today. By extension, this would help explain why investors continue to watch the top biotech stocks . This would be ...

HOOKIPA Pharma Inc. (HOOK) Q4 2020 Results Conference Call March 18, 2021 08:30 AM ET Company Participants Matthew Beck - Head of Investor Relations Joern Aldag - Chief Executive Officer Reinhard Kandera - Chief Financial Officer Igor Matushansky - Chief Medical Officer and Head of Global Res...

HOOKIPA Pharma shares rise ([[HOOK]] +6.7%) after the company posted fourth-quarter results that beat Wall Street estimates, helped partly by higher cost reimbursements received under the collaboration agreement with Gilead during the quarter.Revenue in the quarter was $5.2M up from...

HOOKIPA Pharma (HOOK): Q4 GAAP EPS of -$0.46 beats by $0.13.Revenue of $5.16M (+42.5% Y/Y) beats by $0.9M.Shares +0.7% PM.Press Release For further details see: HOOKIPA Pharma EPS beats by $0.13, beats on revenue

Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidates Follow-on offering strengthened cash basis with $143 million available at year-end to support progression of Human Pap...

NEW YORK and VIENNA, Austria, March 09, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full yea...

Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells 2-vector approach resulted in tumor cures and long-term immunity against tumor rechallenge Publication underscores the...

NEW YORK and VIENNA, Austria, March 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will parti...

NEW YORK and VIENNA, Austria, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will partic...

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics from its arenavirus immune-system reprogrammer platform. Hookipa has an infectious disease/oncology pipeline of six therapeutics. including three in clinical trials including HB-101 f...